IMUX
Immunic, Inc.
1.19
USD
This page is just a preview of the data found in TrendSpider’s full version
Immunic, Inc. stock is up 5.31% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 70% of the previous 9 December’s closed higher than November. In the last 1 Unusual Options Trades, there were 1 CALL.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 10 Oct 16:03 | 17 Jan, 2025 | 3.00 | 293 |
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.
